- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07950267
Real-world Evidence of Inebilizumab in IgG4-RD (REDUCE)
Real-world Evidence of Inebilizumab in Decreasing Corticosteroid Use and Improving Clinical Efficacy in IgG4-RD
The goal of this observational study is to observe the efficacy and safety of inebilizumab in the treatment of IgG4-related disease. The main question it aims to answer the optimal steroid-sparing regimen for patients with IgG4-RD in clinical practice.
This study will enroll all patients with IgG4-RD treated with inebilizumab. Enrolled patients will receive different treatment regimens according to disease severity and whether they are taking other immunosuppressive agents.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
All enrolled patients will be categorized into four subtypes based on disease severity and concomitant use of other immunosuppressive agents:
Group1 Treatment-naive active disease treated with inebilizumab monotherapy group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that the disease is suitable for inebilizumab monotherapy; Group2 Treatment-naive active disease treated with short-course corticosteroids plus inebilizumab group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that short-course corticosteroids are required in combination; Group3 Stable disease continued-treatment group: patients with stable disease control on long-term corticosteroids or corticosteroids plus conventional immunosuppressants, who are at high risk of relapse after discontinuation and are willing to switch to a steroid-free inebilizumab treatment regimen; Group4 Relapsed/refractory patient group: patients who experience relapse while receiving corticosteroids or corticosteroids combined with immunosuppressants.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Linyi Peng
- Telefonnummer: +86-10-69155004
- E-post: drpenglinyi@163.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
All IgG4-related disease patients treated with inebilizumab.
Beskrivelse
Inclusion Criteria:
- Aged ≥18 years old;
- Meet the 2019 ACR/EULAR classification criteria or the 2020 Japanese diagnostic criteria for IgG4-RD;
- Plan to receive treatment with inebilizumab;
- Signed informed consent form.
Exclusion Criteria:
- Pregnant or lactating female patients;
- Participation in other interventional studies within 30 days prior to screening, or exposure to investigational products within 5 half-lives before enrollment, or planned participation in other interventional studies during the trial period;
- Patients with contraindications to inebilizumab treatment;
- Any other conditions deemed inappropriate for enrollment by the investigator.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: CROSS_SECTIONAL
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Patients with IgG4-RD treated with inebilizumab
Patients with IgG4-RD receiving inebilizumab in the real-world setting |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Relapse rate
Tidsramme: One year after inebilizumab treatment
|
Flare of IgG4-RD is defined as the reappearance of previous symptoms or signs of IgG4-RD or the appearance of new symptoms or signs attributed to IgG4-RD, based on clinical assessment, laboratory tests, and/or imaging, and reflected by an increase in the IgG4-RD Responder Index |
One year after inebilizumab treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of subjects achieving flare-free and treatment-free complete remission
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment
|
Flare-free and treatment-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Proportion of subjects achieving flare-free and glucocorticoid-free complete remission
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment
|
Flare-free and glucocorticoid-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Remission rate after inebilizumab treatment
Tidsramme: Six months and twelve months after inebilizumab treatment
|
The investigator determined that there was no evidence of disease activity at the visit |
Six months and twelve months after inebilizumab treatment
|
|
IgG4-RD Responder Index (IgG4-RD RI) after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment
|
Measured by IgG4-RD Responder Index |
Three Months, six months and twelve months after inebilizumab treatment
|
|
IgG4-RD Damage Index (IgG4-RD DI) after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment
|
Measured by IgG4-RD Damage Index |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Changes in serum IgG4 levels from baseline after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment
|
Laboratory markers |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Changes in serum B-cell levels from baseline after inebilizumab treatment
Tidsramme: Three Months, six months and twelve months after inebilizumab treatment
|
Laboratory markers |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Total amount of glucocorticoids during inebilizumab administration
Tidsramme: One year after inebilizumab treatment
|
Total amount of glucocorticoids calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control. This measure accounted for all glucocorticoids treatments administered to participants to manage disease activity throughout the study period. |
One year after inebilizumab treatment
|
|
Improvement in patients' quality of life during inebilizumab administration
Tidsramme: One year after inebilizumab treatment
|
Quality of life measured by the EQ-5D-5L questionnaire |
One year after inebilizumab treatment
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- I-26PJ0909
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD will not be shared with other researchers. Data may be made available to regulatory authorities, trial monitors, auditors, and ethics committees as required for trial oversight, monitoring, audit, and verification.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .